rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

YD Bio Limited -

YDES · Nasdaq

Health CareDiagnostics & LabsAbove a falling average

YDES stood above a rising 150-day average in 0 of the last 25 weekly readings. It is 34.9% above that average now. Diagnostics & Labs: 52% of its 44 stocks in an uptrend (+5 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 25
Industry in uptrend
52% +5 in 4 wk
Insider buys, 12 months
$257K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
11 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 25 weeks.

21 Apr – 20 Oct
16%34%53%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$248KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Ethan Phd ShenCEObought12,700at $3.8514 Sep 2026filed 16 Sep 2026
Ethan Phd ShenCEObought3,100at $3.939 Sep 2026filed 10 Sep 2026
Ethan Phd ShenCEObought18,378at $3.674 Sep 2026filed 8 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders11+3 on the quarter
New · exited3 · 0
Reported value$636K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Garrett Wealth Advisory Group, LLCnew · filed 4 Aug 202684,630$190K+84,630
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202662,714$141K+2,478+4.1%
Cypress Capital Management LLC (WY)added · filed 6 Aug 202633,690$76K+3,000+9.8%
Cerity Partners LLCunchanged · filed 14 Aug 202632,406$73K00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 202630,106$68K+10,656+54.8%
JANE STREET GROUP, LLCnew · filed 14 Aug 202621,423$48K+21,423
UBS Group AGadded · filed 13 Aug 202612,384$28K+756+6.5%
WOLVERINE ASSET MANAGEMENT LLCunchanged · filed 10 Aug 20264,886$11K00.0%
MORGAN STANLEYreduced · filed 13 Aug 2026160$360-63−28.3%
WELLS FARGO & COMPANYnew · filed 14 Aug 202675$169+75
30 Sep 2025 – 30 Jun 2026
81011Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Kochi Chang Company insiderDirector · last 30 Sep 20260 · 0
Shao-Ta Lu Company insiderDirector · last 30 Sep 20260 · 0
Ethan Shen Company insiderCEO · last 14 Sep 20263 · 0

Same industry

CDNA CareDxLeading+94%
NTRA NateraLeading+49%
FTRE Fortrea HoldingsLeading+42%
XGN ExagenLeading+41%
TKNO Alpha TeknovaLeading+36%
PSNL PersonalisLeading+36%
ADPT Adaptive BiotechnologiesLeading+21%
GH Guardant HealthLeading+20%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202528.1%
Operating profit marginFY 2025 · to 31 Dec 2025-883%
Free cash flow marginFY 2025 · to 31 Dec 2024-254%
Return on capital employedFY 2025 · to 31 Dec 2025-43.4%
Research spendFY 2025 · to 31 Dec 2025268%
Revenue growthFY 2025 · to 31 Dec 202445.8%
Share count trendFY 2025 · to 31 Dec 20240.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$6.0M
Free cash flowFY 2025 · to 31 Dec 2025−$8.0M

Analyst forecasts

No analyst forecasts yet.